NKTX vs. ANRO, NATR, PEPG, RVNC, HROW, AMRN, FBLG, HRTX, MRSN, and ORGO
Should you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Alto Neuroscience (ANRO), Nature's Sunshine Products (NATR), PepGen (PEPG), Revance Therapeutics (RVNC), Harrow Health (HROW), Amarin (AMRN), FibroBiologics (FBLG), Heron Therapeutics (HRTX), Mersana Therapeutics (MRSN), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical preparations" industry.
Nkarta (NASDAQ:NKTX) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
Alto Neuroscience has higher revenue and earnings than Nkarta.
Nkarta currently has a consensus target price of $17.83, suggesting a potential upside of 161.49%. Alto Neuroscience has a consensus target price of $32.33, suggesting a potential upside of 128.99%. Given Nkarta's higher probable upside, research analysts plainly believe Nkarta is more favorable than Alto Neuroscience.
Alto Neuroscience's return on equity of 0.00% beat Nkarta's return on equity.
In the previous week, Alto Neuroscience had 3 more articles in the media than Nkarta. MarketBeat recorded 3 mentions for Alto Neuroscience and 0 mentions for Nkarta. Alto Neuroscience's average media sentiment score of 0.20 beat Nkarta's score of 0.00 indicating that Alto Neuroscience is being referred to more favorably in the news media.
Nkarta received 39 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 100.00% of users gave Alto Neuroscience an outperform vote while only 71.43% of users gave Nkarta an outperform vote.
80.5% of Nkarta shares are held by institutional investors. 5.6% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Alto Neuroscience beats Nkarta on 7 of the 11 factors compared between the two stocks.
Get Nkarta News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
